Halozyme Therapeutics reported Q1 2026 revenue of $376.7M (+42.2% YoY), surpassing estimates by 6.1% with $1.60 adjusted EPS.

Investor’s Business Daily cut its suggested exposure to 0% to 20%. The indexes are weak, but money is moving into the stocks ...

NEW YORK, NY -Seven Indian American women have earned a place on Forbes’ 2026 “50 Over 50” list, with four recognized in Innovation and one each in Impact, Investment and Lifestyle. The annual list, ...

10/13/2026 04:44 PM ET Alissa Coram and Ken Shreve walk through Tuesday's market action with a discussion of key stocks to watch in Stock ...

The IBD 50 has just gone through the biggest revision in its history. The new version greatly outperforms the old one, ...

Looking for the best green investments? IBD's 50 Most Sustainable Companies combine high sustainability scores and superior stock ratings.

Teva Pharmaceuticals and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013) in patients with ...

AbbVie today announced the presentation of 22 scientific abstracts from its market-leading inflammatory bowel disease (IBD) portfolio at the American College of Gastroenterology (ACG) 2026 Annual ...

Share on Pinterest Why do IBD patients start reacting to foods they once tolerated? A new study answers why. Yulia Naumenko/Moment/ Getty Images Inflammatory bowel disease (IBD) symptoms are usually ...